UltraShape Power for Abdominal Fat and Circumference Reduction

Excess Abdominal Fat Clinical Trial

Official title:

Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Power Device Using the U-Sculpt Power Transducer for Abdominal Fat and Circumference Reduction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02748928
• Other study ID #: DHF21621
• Status: Completed
• Phase: N/A
• Start date: June 8, 2016
• Est. completion date: April 23, 2018

Study information

• Verified date: March 2019
• Source: Syneron Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, one arm, baseline-controlled, clinical study for the evaluation of the UltraShape Power treatment using the U-Sculpt Power Transducer for non-invasive abdominal fat and circumference reduction.

Description:

Up to 120 healthy adult volunteers, seeking noninvasive abdominal fat and circumference reduction, male and females, 18 to 60 years of age from 6 investigational sites. Eligible subjects will receive 3 bi-weekly treatments (2 weeks interval) with the UltraShape Power device utilizing the U-Sculpt Power Transducer according to the study protocol. Subjects will return for 3 follow-up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment (Third Treatment).

Each subject will be enrolled for total expected study duration of 16 weeks. Subject's abdominal fat thickness and circumference will be measured at the measurements points and will be assessed at each visit. Additionally, a subject questionnaire will be completed in each follow-up visit (4wk, 8wk and 12wk FU). Finally, photography will be performed under visible light conditions of the front, right, left and back view. Most of the assessments will occur at each of the visits (all treatments and all follow-up visits) to the clinic.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: April 23, 2018
• Est. primary completion date: February 15, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

A subject is eligible to participate in the study if he/she meets all the following inclusion criteria:

1. Signed informed consent to participate in the study.

2. Female and male subjects, 18 and 60 years of age at the time of enrollment

3. Fitzpatrick Skin Type I to VI.

4. Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper).

5. Body mass index (BMI): BMI between 22 to 30 (normal to overweight, but not obese).

6. If female, not pregnant or lactating, must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e. oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).

7. In addition, negative urine pregnancy test as tested before each treatment and at the last follow-up visit for women with child-bearing potential (e.g. not menopause).

8. General good health confirmed by medical history and skin examination of the treated area.

9. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.

10. Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.

11. Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations.

Exclusion Criteria:

A subject is not eligible for participation in this study if he or she meets any of the following exclusion criteria:

1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker or defibrillator, abdominal aortic aneurism

2. Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease

3. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions

4. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator

5. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone

6. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction

7. Previous body contouring procedures in the treatment area within 12 months

8. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing

9. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course

10. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area

11. Very poor skin quality (i.e., severe laxity)

12. Abdominal wall diastasis or hernia on physical examination

13. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months

14. Obesity (BMI above 30)

15. Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study

16. Unstable weight within the last 6 months (i.e., ± 3 percent weight change in the prior six months)

17. Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration)

18. Fat thickness lower than 2.5 cm after strapping at the treated area.

19. Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trials)

20. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Related Conditions & MeSH terms

• Excess Abdominal Fat

Intervention

Device:
• UltraShape Power
Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time

Locations

Country	Name	City	State
United States	Jewell Plastic Surgery	Eugene	Oregon
United States	Prana Medical Aesthetics	Jacksonville Beach	Florida
United States	A Womans Touch Plastic Surgery	Louisville	Kentucky
United States	Baumann Cosmetic and Research Institute, Inc	Miami	Florida
United States	DuPage Medical Group	Naperville	Illinois
United States	Union Square Laser Dermatology	New York	New York
United States	Laser Skin Surgery Center of Northern California	Sacramento	California
United States	Syneron Candela Institute for Education Clinic	Wayland	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Syneron Medical

Country where clinical trial is conducted

United States, 

References & Publications (3)

Ascher B. Safety and efficacy of UltraShape Contour I treatments to improve the appearance of body contours: multiple treatments in shorter intervals. Aesthet Surg J. 2010 Mar;30(2):217-24. doi: 10.1177/1090820X09360692. — View Citation

Chang SL, Huang YL, Lee MC, Chang CH, Lin YF, Cheng CY, Hu S. Long-term follow-up for noninvasive body contouring treatment in Asians. Lasers Med Sci. 2016 Feb;31(2):283-7. doi: 10.1007/s10103-015-1852-0. Epub 2015 Dec 29. — View Citation

Moreno-Moraga J, Valero-Altés T, Riquelme AM, Isarria-Marcosy MI, de la Torre JR. Body contouring by non-invasive transdermal focused ultrasound. Lasers Surg Med. 2007 Apr;39(4):315-23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound	Abdominal fat thickness change post UltraShape treatments at 12 weeks follow-up (12wk FU) after final treatment versus baseline	Baseline and 16 weeks (4 weeks treatment + 12 week follow up)
Secondary	Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound	Abdominal fat thickness change as measured by ultrasound post UltraShape Power treatments at 4-week, 8-week and 12-week (from baseline visit) versus baseline	Baseline and at 4, 8, and 12 weeks (from baseline visit)
Secondary	Change in Abdominal Circumference Compared to Baseline	Abdominal circumference change post UltraShape Power treatments	Baseline and at 4, 8, 12 and 16 weeks (from baseline visit)
Secondary	Number of Investigators Reporting Satisfaction With Participants' Treatment Outcome	Satisfaction assessment will be performed independently by the investigator using a 4-point Likert scale questionnaire from 0 = dissatisfied to 3= very satisfied.; The values in the data table reflect the number of Investigators who were "satisfied" or "very satisfied" (i.e., "reported a 2 or 3") with Participant Treatment Outcome, as assessed by the questionnaire.	8, 12 and 16 weeks (from baseline visit)
Secondary	Number of Participants Reporting Satisfaction With Treatment Outcome	Satisfaction assessment will be performed independently by the subjects using a 4-point Likert scale questionnaire from 0 = dissatisfied to 3= very satisfied.; The values in the data table reflect the number of participants who were "satisfied" or "very satisfied" (i.e., "reported a 2 or 3") with Treatment Outcome, as assessed by the questionnaire.	8, 12 and 16 weeks (from baseline visit)
Secondary	Pain Scale for Rating Discomfort Associated With Treatment	Comfort assessment will be performed independently by the subjects using a numerical scale (0-no discomfort to 10-Worst possible discomfort). The subjects will answer this questionnaire after each of the three treatments.	Day 0 (1st treatment), at 2 weeks (2nd treatment) and at 4 weeks (3rd treatment)